Drug Innovation
Commentary
Read the latest on prescription drug pricing
Biden, Sanders Took on ‘Big Pharma’ and Patients Lost
Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Commentary
Read the latest on drug pricing
Cost-Based Pricing For Innovative Medicines Is Unviable And Harmful
Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open (JNO). This study wrongly suggests that cost-based pricing accurately values innovative on-patent medicines, distracts from serious policymaking, and fuels political grandstanding by politicians such as Senator Bernie Sanders. Cost-based pricing could be an economically viable pricing ...
Commentary
Read the latest on US drug pricing
Global Collaboration on Reference Models Will Further Depersonalize Healthcare
By Sally Pipes & Wayne Winegarden Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Commentary
Lawsuit Against Drug Company Could Quash Future Cures
Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Commentary
Read about the latest drug rationing proposals
Let UK Keep Drug Rationing
Any list of the world’s most inhumane healthcare bureaucracies has to include Britain’s National Institute for Health and Care Excellence at the top. For over two decades, the agency has employed ruthless cost-benefit analyses to effectively deny British patients access to the latest medicines. Now NICE is looking to export its expertise rationing ...
Coronavirus
NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Commentary
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Commentary
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Commentary
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Commentary
Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine
By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
Read the latest on prescription drug pricing
Biden, Sanders Took on ‘Big Pharma’ and Patients Lost
Speaking at a White House event with Sen. Bernie Sanders, I-Vt., very recently, President Biden crowed about his rapidly progressing scheme to impose price controls on prescription drugs. “Finally — finally we beat Big Pharma,” he said to Sanders. Unfortunately for Americans — and indeed, patients everywhere — the Democrats’ assault on the drug industry ...
Read the latest on drug pricing
Cost-Based Pricing For Innovative Medicines Is Unviable And Harmful
Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open (JNO). This study wrongly suggests that cost-based pricing accurately values innovative on-patent medicines, distracts from serious policymaking, and fuels political grandstanding by politicians such as Senator Bernie Sanders. Cost-based pricing could be an economically viable pricing ...
Read the latest on US drug pricing
Global Collaboration on Reference Models Will Further Depersonalize Healthcare
By Sally Pipes & Wayne Winegarden Question: What’s worse than government bureaucrats in Washington declaring the value of your medicine? Answer: Bureaucrats from Boston, London, Ottawa and Diemen establishing that value. Unfortunately, this is not a joke. It is the direction that the Institute for Clinical and Economic Review is ...
Lawsuit Against Drug Company Could Quash Future Cures
Like most pharmaceutical companies, Gilead Sciences Inc. devotes a huge amount of time and money to making sure its products are safe for patients. The U.S. Food and Drug Administration approved its drugs to fight HIV, and these medications have worked remarkably well. It then developed the next generation of ...
Read about the latest drug rationing proposals
Let UK Keep Drug Rationing
Any list of the world’s most inhumane healthcare bureaucracies has to include Britain’s National Institute for Health and Care Excellence at the top. For over two decades, the agency has employed ruthless cost-benefit analyses to effectively deny British patients access to the latest medicines. Now NICE is looking to export its expertise rationing ...
NEW BRIEF: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Reforming PBMs Improves the Drug Market and Thwarts Efforts to Socialize Medicine
By Sally Pipes & Wayne Winegarden There they go again. Free-market advocates are jeopardizing pro-market healthcare reforms based on an inability to recognize how cronyism tars the current industry dynamics. That distinction between companies operating in a free market and companies using cronyism to flourish in a government-dominated market is ...
